OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
Zhangxu He, Haomiao Jiao, Qi An, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 1, pp. 291-307
Open Access | Times Cited: 20

Showing 20 citing articles:

Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy
Pengfei Xu, Raoling Ge
European Journal of Medicinal Chemistry (2022) Vol. 230, pp. 114118-114118
Closed Access | Times Cited: 68

NLRP3 Inflammasome Targeting Offers a Novel Therapeutic Paradigm for Sepsis-Induced Myocardial Injury
Yuzi Jin, Joshua S. Fleishman, Yudong Ma, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1025-1041
Open Access | Times Cited: 1

Targeting bromodomain-containing proteins: research advances of drug discovery
Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 18

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases
Zhijie Wang, Li Yin, Zhenghan Xiong, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10824-10848
Closed Access | Times Cited: 13

Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis
Jingrong Shao, Jiao Liu, Shengkai Zuo
Cells (2022) Vol. 11, Iss. 15, pp. 2347-2347
Open Access | Times Cited: 20

A Keap1-recruiting BRD4 Degrader Offers a Single-molecular Polypharmacology Approach for the Treatment of Metabolic Dysfunction-associated Steatohepatitis
Xian Zhang, Yuxin Ge, Mengjie Ye, et al.
Free Radical Biology and Medicine (2025) Vol. 232, pp. 15-27
Closed Access

Design, Synthesis, and Molecular Docking Study of New Indole Derivatives as BRD4 Inhibitors
Gang Jin, Zhangxu He, Feifei Yang, et al.
Russian Journal of Organic Chemistry (2025) Vol. 61, Iss. 2, pp. 280-287
Closed Access

Epigenetic modifications in cardiac fibrosis: recent evidence of new pharmacological targets
M. Sánchez Pérez, Mónica Gómez, Jairo Castellar-López, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access

Reduction-sensitive polymeric carrier for the targeted delivery of a quinazoline derivative for enhanced generation of reactive oxygen species against cancer
Jianrong Cao, Keze Hong, Chengqi Lv, et al.
Biomaterials Science (2024) Vol. 12, Iss. 10, pp. 2626-2638
Closed Access | Times Cited: 3

Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation
Lixin Zhao, Yuguang Zhu, Hua Tao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 8, pp. 3543-3560
Open Access | Times Cited: 3

BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3

Epigenetic Regulation in Myocardial Fibroblasts and Its Impact on Cardiovascular Diseases
Sumra Komal, Yuan Gao, Zhi-Mo Wang, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1353-1353
Open Access | Times Cited: 3

Discovery of 1,2,4-Triazole-3-thione Derivatives as Potent and Selective DCN1 Inhibitors for Pathological Cardiac Fibrosis and Remodeling
Zhangxu He, Ge Gao, Hui Qiao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18699-18723
Closed Access | Times Cited: 2

Unveiling the Mechanisms of Apoptosis Induction by Deep‐Sea‐Derived Polyketide‐Terpenoid Hybrids from Penicillium allii‐sativi: A Focus on Mitochondrial and mTOR Pathways
Chun‐Lan Xie, Taizong Wu, Duo Zhang, et al.
Chinese Journal of Chemistry (2024) Vol. 42, Iss. 24, pp. 3283-3292
Open Access | Times Cited: 2

Identification of novel BRD4 inhibitors by pharmacophore screening, molecular docking, and molecular dynamics simulation
Junmin Dong, Xinghe Wang
Journal of Molecular Structure (2022) Vol. 1274, pp. 134363-134363
Closed Access | Times Cited: 8

Liquid–Liquid Phase Separation Sheds New Light upon Cardiovascular Diseases
Ziyang Cai, Shuai Mei, Zhou Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15418-15418
Open Access | Times Cited: 4

Exploring the landscape of post-translational modification in drug discovery
Yuhao Cao, Tianyi Yu, Zhiguang Zhu, et al.
Pharmacology & Therapeutics (2024) Vol. 265, pp. 108749-108749
Closed Access | Times Cited: 1

Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway
Yaquan Cao, Yang Pu, Yingxue Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115250-115250
Closed Access | Times Cited: 3

Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer
Yingqing Chen, Mingyu Zhang, An‐Xin Wu, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7436-7436
Open Access | Times Cited: 4

BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents
Ragaa Yasser, Kholoud K. Arafa, Nada K. Sedky, et al.
Springer eBooks (2023), pp. 1-29
Closed Access

Page 1

Scroll to top